The therapeutic response of antiviral therapy in HBsAg-positive renal transplant recipients and a long-term follow-up

Hepatology International

Volumn 6, Issue 2, 2012, Pages 449-456

  Hu, Tsung Hui ^a,b   Tsai, Ming Chao ^a   Chen, Yen Ta ^a   Chien, Yu Shu ^a   Hung, Chao Hung ^a   Chen, Te Chuan ^a   Tseng, Po Lin ^a   Chang, Kuo Chin ^a   Yen, Yi Hao ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b FOOYIN UNIVERSITY   (Taiwan)

Author keywords

Hepatitis B virus; Lamivudine; Renal transplantation; Roadmap

Indexed keywords

ADEFOVIR DIPIVOXIL; ASPARTIC ACID; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; METHIONINE; TYROSINE; VIRUS DNA;

ADULT; AGE; AGED; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENDER; GENE MUTATION; GENOTYPE; GRAFT RECIPIENT; HEPATITIS B; HUMAN; IMMUNE DEFICIENCY; KIDNEY GRAFT; LIVER CIRRHOSIS; LONG TERM CARE; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; RECURRENCE RISK; RISK FACTOR; TREATMENT DURATION; VIRUS RESISTANCE;

EID: 84862881523     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-011-9295-6     Document Type: Article

References (48)

1. Fabrizi F, Lunghi G, Poordad FF, Martin P. Management of hepatitis B after renal transplantation: an update. J Nephrol 2002;15:113-122
2. Fabrizi F, Martin P, Dixit V, Kanwal F, Dulai G. HBsAg seropositive status and survival after renal transplantation: metaanalysis of observational studies. Am J Transplant 2005;5: 2913-2921
3. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999;29:257-263
4. Lee WC, Shu KH, Cheng CH, Wu MJ, Chen CH, Lian JC. Longterm impact of hepatitis B, C virus infection on renal transplantation. Am J Nephrol 2001;21:300-306
5. Fabrizi F, Martin P, Ponticelli C. Hepatitis B virus and renal transplantation. Nephron 2002;90:241-251
6. Fornairon S, Pol S, Legendre C, et al. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation 1996;62:297-299
7. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-68
8. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263
9. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996;348:1212-1215
10. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation 2004;77:859-864
11. Durlik M, Lewandowska D. Lamivudine therapy for chronic hepatitis B in renal transplant recipients. Eur J Gastroenterol Hepatol 2004;16:1261-1264
12. Ling R, Mutimer D, Ahmed M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-713
13. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis-Bvirus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:20-22
14. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997;26:1393-1395
15. Gwak GY, Huh W, Lee DH, et al. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy. Transplant Proc 2007;39:3121-3126
16. Chan TM, Tse KC, Tang CS, Lai KN, Ho SK. Prospective study on lamivudine-resistant hepatitis B in renal allograft recipients. Am J Transplant 2004;4:1103-1109
17. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap formanagement of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5:890-897
18. Liu CJ, Chen PJ, Lai MY, et al. Viral factors correlate with hepatitis B e antigen seroconversion in patients with chronic hepatitis B. Liver Int 2006;26:949-955
19. Chen CH, Lee CM, Lu SN, et al. Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan. J Clin Microbiol 2005;43:6000-6006
20. Hung CH, Lu SN, Wang JH, et al. Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virusrelated cirrhosis. J Gastroenterol 2003;38:153-157
21. Lee CM, Chen CH, Lu SN, et al. Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan. Scand J Gastroenterol 2003;38:95-101
22. Mizokami M, Nakano T, Orito E, et al. Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns. FEBS Lett 1999;450:66-71
23. Harnett JD, Zeldis JB, Parfrey PS, et al. Hepatitis B disease in dialysis and transplant patients. Further epidemiologic and serologic studies. Transplantation 1987;44:369-376
24. Rao KV, Kasiske BL, Anderson WR. Variability in the morphological spectrum and clinical outcome of chronic liver disease in hepatitis B-positive and B-negative renal transplant recipients. Transplantation 1991;51:391-396
25. Han DJ, Kim TH, Park SK, et al. Results on preemptive or prophylactic treatment of lamivudine in HBsAg (+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence. Transplantation 2001;71:387-394
26. Park SK, Yang WS, Lee YS, et al. Outcome of renal transplantation in hepatitis B surface antigen-positive patients after introduction of lamivudine. Nephrol Dial Transplant 2001;16:2222-2228
27. Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 2002;36: 1246-1252
28. Thabut D, Thibault V, Bernard-Chabert B, et al. Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B. Eur J Gastroenterol Hepatol 2004;16:1367-1373
29. Kamar N, Sandres-Saune K, Ribes D, et al. Effects of long-term lamivudine therapy in renal-transplant patients. J Clin Virol 2004;31:298-303
30. Kletzmayr J, Watschinger B, Muller C, et al. Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients. Transplantation 2000;70:1404-1407
31. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006;4:936-962
32. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003;38:533-540
33. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005;25:472-489
34. Lok AS. Lamivudine therapy for chronic hepatitis B: is longer duration of treatment better? Gastroenterology 2000;119:263-266
35. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-572
36. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-180
37. Lau DT, Khokhar MF, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32:828-834
38. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:785-791
39. Huang YW, Liu CJ, Lai MY, et al. Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: a retrospective case series. Clin Ther 2006;28:1327-1334
40. Tsai MC, Chen CH, Lee CM, et al. The role of HBV genotype, core promoter and precore mutations in advanced liver disease in renal transplant recipients. J Hepatol 2009;50:281-288
41. Liaw YF. The current management of HBV drug resistance. J Clin Virol 2005;34:S143-S146
42. Hashimoto Y, Suzuki F, Hirakawa M, et al. Clinical and virological effects of long-term (over 5 years) lamivudine therapy. J Med Virol 2010;82:684-691
43. Burger DM, Verweel G, Rakhmanina N, et al. Age-dependent pharmacokinetics of lamivudine in HIV-infected children. Clin Pharmacol Ther 2007;81:517-520
44. Kawaoka T, Suzuki F, Akuta N, et al. Efficacy of lamivudine therapy in elderly patients with chronic hepatitis B infection. J Gastroenterol 2007;42:395-401
45. Heald AE, Hsyu PH, Yuen GJ, Robinson P, Mydlow P, Bartlett JA. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother 1996;40:1514-1519
46. Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 1999;36: 41-66
47. Moore KH, Yuen GJ, Raasch RH, et al. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin Pharmacol Ther 1996;59:550-558
48. Terrault NA, Tran TT, Schiff E, et al. Pharmacokinetics of tacrolimus co-administered with adefovir dipivoxil to liver transplant recipients. Liver Int 2009;29:1178-1183